Lipoxen develops Indian vaccines

Published: 1-Apr-2005


London-based Lipoxen Technologies, a drug and vaccine delivery technology provider, has signed an agreement with Serum Institute of India to develop eight new Lipoxen products in India. The agreement combines Lipoxen's strengths in IP and innovation in the drug delivery field with Serum Institute of India's expertise in clinical development and manufacture.

Providing for clinical trials, licensing, manufacturing and distribution of eight Lipoxen products by the Indian company, the deal includes protein drugs, anti-cancer drugs and vaccines to fight illnesses such as pneumonia, rabies and Haemophilus influenzae B.

The support of UK Trade & Investment was crucial to securing the deal. 'Lipoxen's successful tender for this substantial contract clearly demonstrates what British companies can achieve in exporting to growing markets with world class products and the right support, such as the help and advice provided on the ground by UK Trade & Investment,' said Patricia Hewitt, secretary of state for Trade & Industry. 'India has one of the world's fastest growing economies and offers tremendous potential for UK firms.'

You may also like